Molev

Quick links to important sections

Molev

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Molev

Quick Facts

Property Description
Active Ingredient Mometasone Furoate
Pharmacological Class Corticosteroid (Glucocorticoid)
Forms Cream, Ointment, Lotion, Solution
Route Topical (Applied to the skin)
General Purpose Relieves swelling, itching, and redness
Origin Synthetic

Defining Molev: A Potent Topical Corticosteroid

Molev is a prescription medicine that uses Mometasone Furoate as its active component, a highly effective synthetic glucocorticoid engineered for application on the skin. It belongs to the class of topical corticosteroids and is clinically recognized for its potent anti-inflammatory activity, distinguishing it from lower-strength over-the-counter options. Mometasone Furoate acts as a synthetic topical glucocorticoid receptor agonist with anti-inflammatory, anti-pruritic, and vasoconstrictive properties, which function in reducing skin irritation. For the patient, this means the medicine is specifically designed to calm the excessive activity causing inflammation and discomfort on the skin, often being selected for treating severe contact dermatitis.

Forms and Composition

The composition of Molev consists of the single-ingredient product, Mometasone Furoate, combined with various pharmaceutical base/vehicles to enable its effective topical administration. The drug is available as an ointment, a lighter cream, a more fluid lotion, or a specialized solution. The vehicle—such as the dense, occlusive base found in an ointment—significantly influences the ingredient's penetration and effectiveness on different types of skin problems. Having different forms ensures the medicine can be applied effectively, whether the skin is very dry, moist, or covered in hair.

General Function: Relieving Inflammation and Itching

The primary function of Molev is to provide powerful suppression of local inflammation. Its anti-inflammatory action delivers relief from persistent pruritus (itching), as well as the swelling and redness (erythema) that accompany various skin conditions. It is characterized by a rapid onset of antipruritic action. By controlling these key symptoms, the medicine fulfills its general purpose of stabilizing and restoring the comfort of irritated skin.

Regulatory References

  1. National Cancer Institute
  2. Mometasone Furoate definition
  3. Mometasone Topical

What side effects are possible with Molev?

Serious and Clinically Significant Safety Concerns

The most serious documented risk associated with Molev is the occurrence of neuropsychiatric events. A Boxed Warning is required on the regulatory label to highlight the risk of these events, which have been reported in patients with and without a history of psychiatric illness. Examples of these serious effects include agitation, aggression, depression, sleep disturbances, hallucinations, and suicidal thoughts or behavior.

Due to this risk, the use of Molev for allergic rhinitis is reserved for patients who have not responded adequately to alternative therapies or who cannot tolerate them. The drug is not indicated for the treatment of acute asthma attacks.

Another serious safety consideration is the reporting of systemic eosinophilia, which in rare instances has presented with clinical features consistent with Churg-Strauss syndrome (an eosinophilic granulomatosis with polyangiitis).

Common Adverse Reactions

Adverse reactions reported at a common frequency (ge 5% incidence and greater than placebo in clinical trials) primarily involve the nervous and respiratory systems. These may include headache, upper respiratory infection, pharyngitis, cough, fever, abdominal pain, diarrhea, and otitis media.

Safety Limitations and Precautions

  • The drug is contraindicated in patients with known hypersensitivity to any component.
  • It should not be abruptly substituted for inhaled or oral corticosteroids.
  • Patients with Phenylketonuria (PKU) should be aware that the chewable tablet formulation contains aspartame, a source of phenylalanine.
  • Individuals with known aspirin sensitivity must continue to avoid aspirin and non-steroidal anti-inflammatory agents while on this medication.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mometasone Furoate topical products defines overdose as the potential for systemic absorption following extensive or prolonged use, especially when applied to large surface areas or under occlusive dressings.

Overdose Risk & Manifestations Regulatory Guidance
Systemic Effects Reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, the primary documented systemic effect.
Clinical Signs Manifestations resembling Cushing's syndrome, hyperglycemia, and glucosuria are documented in regulatory materials.
Population Risk Pediatric patients have officially documented greater susceptibility to systemic toxicity due to a higher skin surface area-to-body weight ratio.

Emergency Action and Medical Attention

Urgent medical attention is necessary to determine the need for periodic evaluation of HPA axis function. Testing tools cited in regulatory documentation include the ACTH stimulation test, used to confirm the suppression.

Management of documented HPA axis suppression requires medical supervision to initiate the gradual withdrawal of the drug, a reduction in application frequency, or the substitution with a less potent corticosteroid. Supplemental systemic corticosteroids may be required in cases of confirmed glucocorticosteroid insufficiency. These required procedural steps structure the official regulatory guidance on managing systemic exposure.

Therapeutic Uses of Molev

What Molev Treats: Main Uses and Benefits

Symptomatic Support for Inflammatory Dermatoses

The primary role of Molev (topical Mometasone Furoate) is in the symptomatic management of skin conditions characterized by inflammation. It is a corticosteroid relevant for the relief of the inflammatory and pruritic manifestations observed in corticosteroid-responsive dermatoses.

This medication is commonly used in conditions presenting with acute episodes, relevant in cases of chronic inflammatory diseases such as psoriasis and atopic dermatitis (eczema). It helps address symptom clusters that are intense or disruptive, including pronounced pruritus (itching), visible redness (erythema), and associated swelling. Applied during phases when symptoms intensify, it is relevant when supportive symptom management is appropriate.

Molev is used across domains where additional symptomatic support is needed in addressing these signs of skin irritation, providing support that may help ease the overall symptom load and contributes to general well-being during symptomatic periods.

“The goal of symptomatic support is to assist in managing affected skin areas and contribute to maintaining functional stability.”


QuickFact

Property Description
Quick Fact: Used for managing Pruritus and Inflammation
Core Symptom: Intense itching and skin redness
Typical Context: Acute flare-ups of chronic skin conditions
Main Benefit: Supports easing overall symptom load

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who can and cannot use Molev?

Classification Regulatory Status
Eligible Age Groups Adults and children aged 2 years and older (Cream/Ointment).
Not Recommended Children below 2 years of age, as safety and efficacy have not been established.
Absolute Contraindication Known hypersensitivity to any component; untreated viral, fungal, or bacterial skin infections; rosacea; acne vulgaris; or perioral dermatitis.

The eligibility for using Molev (Mometasone Furoate topical) is strictly defined by regulatory authorities to ensure proper use. The medicine is authorized for adults and most children two years of age and older. Its use is formally contraindicated for treating specific skin conditions like acne, rosacea, and areas with untreated infections.

Furthermore, use is restricted on highly sensitive areas, and application on the face, groin, or underarms should be avoided. The medicine must not be used with occlusive dressings (e.g., diapers) unless directed by a physician. For pregnancy (FDA Category C), the drug should be used only if the potential benefit justifies the potential risk. Caution is advised during lactation, and application to the breast area must be avoided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Molev (Topical Mometasone Furoate) is governed by the potential for systemic absorption of the active ingredient, which exposes it to common metabolic pathways and pharmacodynamic class effects.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors may cause a pharmacokinetic interaction. Mometasone furoate is metabolized by the CYP3A4 enzyme, and co-administration with inhibitors such as ritonavir or cobicistat can lead to a reduction of clearance and increased systemic exposure of the corticosteroid. Regulatory documents classify the use of these strong inhibitors as requiring caution due to this exposure risk.

Interaction-Related Restrictions

Interaction Type Interacting Substance/Class Official Outcome/Restriction
Pharmacodynamic Reinforcement Other Corticosteroid-containing products Restriction due to risk of additive systemic effects and potential for HPA axis suppression.
Metabolic Interference Strong CYP3A4 Inhibitors Increased systemic exposure due to reduced clearance.

Population-Specific Considerations

The official labeling notes that patients with Hepatic Impairment or Liver Disease are at a higher risk of systemic effects from interactions. This increased susceptibility is due to the slower clearance of the drug from the body, which prolongs exposure and heightens the potential for interaction-related outcomes.

Mechanism of Action

The mechanism begins as the drug, a Glucocorticoid Receptor (GR) agonist, binds to the receptor within the cell's cytoplasm. This complex then moves to the nucleus to actively modulate gene transcription by both turning on (transactivating) anti-inflammatory genes and turning off (transrepressing) genes responsible for pro-inflammatory signals like cytokines and chemokines. This fundamental change in gene expression results in the dampening of pro-inflammatory signaling sequences. A key consequence of gene modulation is the increased synthesis of anti-inflammatory proteins, notably Lipocortin-1. This protein acts as an indirect inhibitor of the enzyme Phospholipase A2 (PLA2), which consequently limits the formation of chemical mediators such as prostaglandins and leukotrienes. By cutting off this precursor, the mechanism reduces the local production of inflammatory mediators. Concurrently, the drug's activity influences local blood vessel dynamics, leading to vasoconstriction and a reduction in capillary permeability. These physiological changes physically limit the local accumulation and migration of immune cells and result in decreased vessel permeability and reduced local accumulation of fluid and immune cells.

Dosage and Administration Information

How to Use Molev: Official Administration Guidelines

Molev (Topical Mometasone Furoate 0.1%) is administered strictly for external use on the skin. The medication is applied once daily using the appropriate formulation: a thin film of the cream or ointment, or a few drops of the lotion or solution, which should be massaged gently into the affected area. Application must be avoided on highly sensitive membranes, and the product is not for oral, ophthalmic, or intravaginal use.


Official Usage Constraints

The treatment protocol is structured around time-limited use and specific application techniques. Therapy should be discontinued when control of the condition is achieved. If no improvement is observed within two weeks, a professional reassessment of the condition is recommended.

Constraint Area Official Procedural Rule
Occlusion Do not use with occlusive dressings (e.g., bandages, diapers) unless specifically directed, as this increases absorption.
Specific Sites Avoid application to the face, groin, or axillae without explicit instruction from a healthcare provider.
Hygiene Hands must be washed after each application.

Population-Specific Administration

The minimum age for use is defined by the specific formulation. The cream and ointment forms are approved for pediatric patients 2 years of age and older, while the lotion/solution is typically approved for patients 12 years of age and older. Continuous use for longer than three weeks in pediatric patients is not established, and the treated area is generally limited to a maximum of 10% of the body surface area in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Molev (Topical Mometasone Furoate)

The research investigating Mometasone Furoate focuses primarily on evidence from controlled clinical studies, as documented in official scientific sources. The aim of this section is to provide context on the type of research that has been conducted and what those studies have explored, without offering clinical recommendations.


Evidence for Use in Plaque Psoriasis

The research exploring Mometasone Furoate for plaque psoriasis was conducted through short-term Randomized Controlled Trials (RCTs), including individuals with mild to moderate disease severity. These studies were used in research exploring how symptoms change over defined time intervals. Studies monitored outcomes related to the visual signs of the condition, such as erythema (redness), scaling, and plaque thickness, alongside the subjective symptom of pruritus (itching).

Research describes patterns observed in the studies over typical treatment periods lasting up to six to eight weeks. However, there is limited information for long-term outcomes for continuous use, as the follow-up durations were limited.

Evidence for Use in Atopic Dermatitis (Eczema)

Mometasone Furoate was studied for atopic dermatitis, a condition characterized by fluctuating or episodic manifestations. The evidence base includes numerous RCTs and subsequent systematic reviews. Research examined outcomes capturing phases of heightened symptom activity, such as intense itching and visible redness, measured by standardized clinical scores.

Findings describe patterns observed in patient-reported experiences over short study periods, typically two to four weeks. The evidence involves studies that included both adults and different age groups of children. Research describes the medicine being studied in children, but follow-up durations were limited for very young subjects, often to three weeks.

Research Gaps and Unanswered Questions

The evidence highlights what is known—and what is still uncertain—about Mometasone Furoate. A primary limitation is that long-term effects are not fully established; the majority of published research provides insight into short-term changes. Comparative evidence is lacking for certain indications, and research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. Mometasone Furoate Topical Cream 0.1% Drug Information (DailyMed)
  2. Topical Corticosteroids: Therapeutic Use and Applications
  3. Guidance on the use of topical corticosteroids in the management of eczema

Frequently Asked Questions (FAQ)

Common questions about Molev (FAQ)


Q: How quickly does Molev typically start to work?

Official documents state that the drug's mechanism is associated with a rapid onset of anti-inflammatory and anti-pruritic (anti-itching) relief at the application site.


Q: Is it true that Molev can cause [specific, common, but non-severe side effect]?

Regulatory labeling requires that all adverse reactions identified in clinical trials be documented. This official information serves as the authoritative source for verifying if a specific symptom or effect is associated with the medicine.


Q: Does Molev interact with over-the-counter pain relievers?

The official label includes a precaution regarding non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin. The guidance indicates that for individuals with known aspirin sensitivity, avoidance of aspirin and other NSAIDs is advised while using this medicine, as this is a general safety precaution associated with the drug.


Q: Can I take Molev if I have a history of [common organ] problems?

Official documents advise caution for individuals with impaired liver function or liver disease. This is because hepatic impairment can lead to a slower clearance of the drug from the body, potentially increasing the risk of systemic effects.


Q: Is Molev safe to take for long periods of time?

Regulatory research primarily focuses on the typical short-term treatment durations of a few weeks. Official research summaries indicate that there is limited established evidence regarding the safety and outcomes associated with continuous, long-term use beyond those typical treatment periods.


Q: If I stop taking Molev suddenly, what can I expect?

Official documents caution that abrupt substitution of Molev for systemic steroid medications (like oral or inhaled corticosteroids) is not recommended. This warning is due to the potential risk of systemic effects, such as suppression of the HPA axis, a mechanism that controls the body's natural cortisol production.


Q: How does Molev affect the [affected bodily system, e.g., nervous system]?

Official labeling includes a Boxed Warning regarding the possibility of neuropsychiatric events, which are known to involve effects on the nervous system. The drug's mechanism of action involves acting on glucocorticoid receptors to reduce inflammation at the cellular level.


Q: Why do some people say Molev didn't work for them?

Studies and official information indicate that the research describes overall patterns observed in a group of patients. These studies do not determine whether a specific individual will experience the same result, meaning individual response to the medication can vary.


Q: Does Molev need to be taken at a specific time of day?

According to the official administration instructions, the medication is required to be applied only once daily. The regulatory documents do not specify a particular time of day, such as morning or evening, for application.


Q: Is it normal to feel [mild, non-serious symptom] when first starting Molev?

Regulatory documents list the most common adverse reactions (ge 5%) observed in clinical trials, which may include mild, transient symptoms such as headache or skin irritation. Official product information describes these as common occurrences but does not classify them as expected or otherwise at the start of treatment.


Q: What happens if Molev stops working after a period of time?

Official guidance indicates that if a condition was initially controlled but then worsens, or if the drug appears to stop working, professional reassessment of the diagnosis is recommended according to regulatory guidance. This allows for determination of the cause of the change in response.


Q: If I miss a dose of Molev, what is the guidance on what to do?

Official guidelines advise the procedure for a missed dose is to apply it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the guidance recommends skipping the missed one to resume the regular schedule.


Q: Are there any specific foods or drinks to avoid while taking Molev?

Regulatory information states that no specific foods or drinks are known to interact with the topical formulation of this medicine.


Q: How long does Molev stay in your system after stopping treatment?

The pharmacokinetic properties of the drug are described in regulatory documents, including its half-life. This information indicates that clearance from the systemic circulation typically occurs over a defined period of time after the medication is discontinued.


Q: Do older adults use a different form of Molev?

Regulatory documents state that a specific adjustment in the form or dosage is not required for elderly patients based on age alone. However, caution is generally advised for this population due to a potentially higher susceptibility to systemic effects.


Q: Are there any known differences in how Molev works for men versus women?

Based on regulatory clinical data, no clinically significant differences in how the drug works were observed in the safety or efficacy profiles between male and female patients studied.


Q: Does Molev require any special monitoring or lab tests?

Official guidance related to the potential for systemic absorption and HPA axis suppression notes that appropriate laboratory testing may be considered for patients who are prescribed high-dose or long-term treatment.


Q: What is the risk of developing a dependency on Molev?

Official documents warn that prolonged topical use carries a risk of local skin dependency, also known as tachyphylaxis. Abrupt withdrawal after long-term use may also lead to a rebound phenomenon.


Q: Is Molev a controlled substance?

Regulatory sources confirm that the active ingredient, Mometasone Furoate, is not classified as a scheduled controlled substance under the federal Controlled Substances Act.


Q: Can Molev affect my ability to drive or operate machinery?

The regulatory label states that, given its topical route of administration and side-effect profile, this medicine is not expected to affect a person’s ability to drive or operate machinery.


Q: What if I'm taking herbal supplements—do they interact with Molev?

Regulatory documents focus on known interactions with prescription drugs that affect metabolic pathways, such as CYP3A4 inhibitors. General product guidance recommends informing a healthcare provider of all supplements being taken, even though specific herbal supplements are not named.


Q: Does Molev interact with birth control pills?

Regulatory reviews of co-administration have not indicated a known interaction between the topical formulation of Molev and oral contraceptives (birth control pills).


Q: What should I know about taking Molev if I have diabetes?

Regulatory documents include a warning for patients with diabetes mellitus. This is because topical corticosteroids may, in rare instances due to systemic absorption, cause changes such as hyperglycemia (raised blood sugar) or glycosuria (sugar in urine).


Q: Does my diet change how well Molev is absorbed?

Regulatory documents confirm that the systemic absorption of the topical medicine is influenced by factors like the integrity of the skin barrier and the formulation used (e.g., cream versus ointment). This absorption is not affected by a person's diet.


Q: If I am taking Molev, can I still get certain vaccinations?

The label states that patients receiving high doses or long-term systemic corticosteroids are advised to avoid live attenuated vaccines. Although topical absorption of Molev is generally limited, official guidance suggests caution regarding vaccines.


Q: What happens if a child accidentally takes Molev?

Regulatory guidance for accidental oral ingestion notes that a single event is unlikely to produce systemic toxicity due to low bioavailability. However, regulatory guidance strongly advises seeking immediate medical consultation for any accidental ingestion.


Q: Is there a generic version of Molev available?

Regulatory approval records confirm that the active ingredient, Mometasone Furoate, is available in generic formulations after the relevant patents have expired.


Q: Can stress or illness change how Molev works?

Regulatory documents warn that severe skin conditions can lead to increased systemic absorption of the drug. If stress or illness affects the integrity of the skin barrier, this could potentially alter systemic exposure.


Q: Does Molev cause weight gain or loss?

Weight gain or loss is not listed as a common adverse reaction in regulatory documents. However, high systemic absorption can rarely lead to signs of hypercorticism, which can sometimes involve changes in weight.


Q: Is Molev considered a 'new' drug or has it been around for a while?

Regulatory approval dates confirm that the active ingredient, Mometasone Furoate, has been marketed for several decades. It is therefore considered a well-known and established active ingredient.


Q: What is the difference between the brand-name Molev and the generic equivalent?

Regulatory guidance confirms that generic formulations contain the identical active ingredient as the brand-name product. Generic versions must also meet the same rigorous standards of quality and performance established by regulatory authorities.


Q: Is Molev known to interact with alcohol?

Regulatory labeling does not specify a known interaction between the topical drug and the consumption of alcohol.


Q: Does Molev interact with common supplements like Vitamin D or fish oil?

Regulatory documents focus on drug-drug interactions, particularly those affecting the CYP3A4 metabolic pathway. Official labeling does not list specific interactions with common nutritional supplements such as Vitamin D or fish oil.


Q: What if I take too much Molev?

Official guidance states that chronic overdose can occur due to increased systemic absorption over a prolonged period, which may lead to signs of hypercorticism. Management of this condition typically involves gradual reduction of the drug under professional supervision.


Q: Is Molev used as a preventive medicine?

Regulatory indications describe the drug’s use for the relief of inflammatory and pruritic manifestations of certain skin conditions. Therefore, it is used to treat existing symptoms rather than for primary prevention.

How should Molev be stored and disposed of?

How to Store and Dispose of Molev?

Official storage and disposal requirements for Molev (topical Mometasone Furoate) are established to ensure product stability and safety, as documented in regulatory labeling.

Storage Conditions

Molev must be stored at Controlled Room Temperature, typically 25 C (77 F), with temperature excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be kept in the container it came in and maintained tightly closed. It must be protected from both freezing and excessive heat, and stored away from excess moisture or direct light. For child safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Molev should not be disposed of in household waste or poured down a drain or toilet. Disposal should adhere to local pharmaceutical waste guidelines, often accomplished by returning the product to a pharmacist or utilizing a registered drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Molev found in:

A-Z Index: